WS #13306
Reports of AstraZeneca-Bristol Myers merger talks send AZN shares down 6.7% as investors question the strategic logic.
AstraZeneca-Bristol Myers merger talks
Reports of AstraZeneca-Bristol Myers merger talks send AZN shares down 6.7% as investors question the strategic logic.